Paul Hastings LLP advised J.P. Morgan Securities LLC as the exclusive placement agent in the transaction. Leap Therapeutics, Inc. (Nasdaq:LPTX) has entered into a securities purchase agreement with...
Leap Therapeutics’ $40 Million Private Placement
Century Therapeutics’ $60 Million Private Placement
Paul Hastings LLP advised BofA Securities as the sole placement agent in the transaction. Century entered into a securities purchase agreement with a select group of...
Skye Bioscence’s $40 Million Private Placement Equity Financing
Paul Hastings LLP advised Piper Sandler and Co. as lead placement agent, and Oppenheimer & Co. as placement agent in the transaction. Skye Bioscience, Inc. (OTCQB:...
Lexeo Therapeutics’ $95 Million Private Placement
Paul Hastings LLP advised J.P. Morgan and Leerink Partners as co-lead placement agents, and Stifel co-placement agent, in the transaction. Lexeo Therapeutics, Inc. (Nasdaq: LXEO) has entered...
Humacyte’s $40 Million Public Offering
Covington & Burling represented Humacyte, while Paul Hastings advised TD Cowen, Cantor and BTIG in the offering. Humacyte, Inc. executed an underwritten public offering of 13,400,000 shares...
PepGen’s $80.1 Million Offering
Paul Hastings LLP advised Leerink Partners on the matter. PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the...
Skye Bioscience’s $50.25 Million Private Placement
Paul Hastings LLP advised the lead placement agent and the placement agent. Skye Bioscience, Inc. (OTCQB: SKYE), a clinical stage biotechnology company focused on the discovery,...
Esperion Therapeutics’ $85.1 Million Public Offering
Paul Hastings LLP advised Jefferies LLC as sole book running manager in connection with Esperion Therapeutics, Inc.’s offering. Esperion Therapeutics, Inc. announced the pricing of its...
Harpoon Therapeutics’ $150 Million Private Placement
Paul Hastings LLP advised TD Cowen and the placement agents in connection with Harpoon Therapeutics’ offering. Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T...
Lexeo Therapeutics’ $100 Million Initial Public Offering
Paul Hastings LLP advised the underwriters in connection with Lexeo Therapeutics’ IPO. Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to transforming...
CymaBay Therapeutics’ $258.75 Million Follow-On Offering
Cooley advised CymaBay, and Paul Hastings advised the representatives of the underwriters. CymaBay Therapeutics, Inc. announced its $258.75 million follow-on offering of common stock and pre-funded...
Acrivon Therapeutics’ $99.4 Million Initial Public Offering
Goodwin Procter advised the underwriters on the deal. Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines...